- Home
- SRG vs ACRS Comparison
SRG vs ACRS Comparison
Compare SRG & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRG
- ACRS
- Stock Information
- Founded
- SRG 2014
- ACRS 2012
- Country
- SRG United States
- ACRS United States
- Employees
- SRG N/A
- ACRS N/A
- Industry
- SRG Real Estate Investment Trusts
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- SRG Real Estate
- ACRS Health Care
- Exchange
- SRG Nasdaq
- ACRS Nasdaq
- Market Cap
- SRG 163.3M
- ACRS 165.7M
- IPO Year
- SRG 2015
- ACRS 2015
- Fundamental
- Price
- SRG $3.29
- ACRS $1.70
- Analyst Decision
- SRG
- ACRS Strong Buy
- Analyst Count
- SRG 0
- ACRS 9
- Target Price
- SRG N/A
- ACRS $9.25
- AVG Volume (30 Days)
- SRG 79.7K
- ACRS 1.3M
- Earning Date
- SRG 08-13-2025
- ACRS 08-06-2025
- Dividend Yield
- SRG N/A
- ACRS N/A
- EPS Growth
- SRG N/A
- ACRS N/A
- EPS
- SRG N/A
- ACRS N/A
- Revenue
- SRG N/A
- ACRS $17,777,000.00
- Revenue This Year
- SRG N/A
- ACRS N/A
- Revenue Next Year
- SRG N/A
- ACRS $8.11
- P/E Ratio
- SRG N/A
- ACRS N/A
- Revenue Growth
- SRG N/A
- ACRS N/A
- 52 Week Low
- SRG $2.43
- ACRS $1.05
- 52 Week High
- SRG $5.25
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- SRG 58.23
- ACRS 65.16
- Support Level
- SRG $3.20
- ACRS $1.51
- Resistance Level
- SRG $3.36
- ACRS $1.78
- Average True Range (ATR)
- SRG 0.14
- ACRS 0.09
- MACD
- SRG 0.01
- ACRS 0.01
- Stochastic Oscillator
- SRG 68.25
- ACRS 76.47
About SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, and leasing of diversified and mixed-use properties throughout the United States.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.